Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig W Spellman

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
The Journal of the American Osteopathic Association|January 24, 2012
Incorporating glucagon-like peptide-1 receptor agonists into clinical practiceCraig W Spellman
The Journal of the American Osteopathic Association|March 11, 2011
Pharmacology of GLP-1 agonists: describing the therapeutic potential to patientsCraig W Spellman
The Journal of the American Osteopathic Association|February 8, 2003
Strategies for optimizing lipid treatment outcomesCraig W Spellman
The Journal of the American Osteopathic Association|May 20, 2009
Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factorsCraig W Spellman
The Journal of the American Osteopathic Association|April 13, 2010
Pathophysiology of type 2 diabetes: targeting islet cell dysfunctionCraig W Spellman
The Journal of the American Osteopathic Association|February 8, 2003
Combination therapy for dyslipidemiaCraig W Spellman
The Journal of the American Osteopathic Association|September 10, 2003
Management of diabetes in the real world: tight control of glucose metabolismCraig W Spellman
The Journal of the American Osteopathic Association|August 8, 2007
Insulin therapy for maximal glycemic control in type 2 diabetes mellitusCraig W Spellman
The Journal of the American Osteopathic Association|September 19, 2007
Islet cell dysfunction in progression to diabetes mellitusCraig W Spellman
The Journal of the American Osteopathic Association|June 28, 2008
Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone lossCraig W Spellman
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
The Journal of the American Osteopathic Association|January 24, 2012
Incorporating glucagon-like peptide-1 receptor agonists into clinical practiceCraig W Spellman
The Journal of the American Osteopathic Association|March 11, 2011
Pharmacology of GLP-1 agonists: describing the therapeutic potential to patientsCraig W Spellman
The Journal of the American Osteopathic Association|February 8, 2003
Strategies for optimizing lipid treatment outcomesCraig W Spellman
The Journal of the American Osteopathic Association|May 20, 2009
Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factorsCraig W Spellman
The Journal of the American Osteopathic Association|April 13, 2010
Pathophysiology of type 2 diabetes: targeting islet cell dysfunctionCraig W Spellman
The Journal of the American Osteopathic Association|February 8, 2003
Combination therapy for dyslipidemiaCraig W Spellman
The Journal of the American Osteopathic Association|September 10, 2003
Management of diabetes in the real world: tight control of glucose metabolismCraig W Spellman
The Journal of the American Osteopathic Association|August 8, 2007
Insulin therapy for maximal glycemic control in type 2 diabetes mellitusCraig W Spellman
The Journal of the American Osteopathic Association|September 19, 2007
Islet cell dysfunction in progression to diabetes mellitusCraig W Spellman
The Journal of the American Osteopathic Association|June 28, 2008
Aggressively managing type 2 diabetes mellitus, hyperlipidemia, and bone lossCraig W Spellman
Pageof 2